Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Sells 581 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 581 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $27.20, for a total transaction of $15,803.20. Following the completion of the sale, the chief financial officer now directly owns 122,766 shares of the company’s stock, valued at $3,339,235.20. The trade was a 0.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, November 12th, Troy Wichterman sold 147 shares of BioLife Solutions stock. The stock was sold at an average price of $26.19, for a total transaction of $3,849.93.
• On Wednesday, October 30th, Troy Wichterman sold 894 shares of BioLife Solutions stock. The shares were sold at an average price of $23.15, for a total transaction of $20,696.10.
• On Monday, September 16th, Troy Wichterman sold 611 shares of BioLife Solutions stock. The shares were sold at an average price of $25.12, for a total transaction of $15,348.32.

BioLife Solutions Stock Up 1.1 %

NASDAQ BLFS traded up $0.31 during trading hours on Friday, reaching $27.47. 200,092 shares of the company traded hands, compared to its average volume of 388,973. The company has a 50 day moving average of $24.19 and a two-hundred day moving average of $23.19. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 12 month low of $11.91 and a 12 month high of $28.88. The stock has a market capitalization of $1.27 billion, a PE ratio of -25.92 and a beta of 1.88.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Mark Sheptoff Financial Planning LLC bought a new position in shares of BioLife Solutions in the 3rd quarter worth about $28,000. 1620 Investment Advisors Inc. bought a new position in shares of BioLife Solutions in the 2nd quarter worth about $35,000. Isthmus Partners LLC lifted its position in shares of BioLife Solutions by 34.4% in the 2nd quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 42,265 shares during the last quarter. Quest Partners LLC bought a new position in shares of BioLife Solutions in the 3rd quarter worth about $57,000. Finally, GAMMA Investing LLC lifted its position in shares of BioLife Solutions by 29.4% in the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after buying an additional 748 shares during the last quarter. 93.24% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on BLFS. HC Wainwright lowered their price target on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a report on Monday, November 18th. TD Cowen raised their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Craig Hallum raised their price target on shares of BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, Northland Securities raised their price target on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.50.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.